UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Pirfenidone Reduces Respiratory-related Hospitalizations in Idiopathic Pulmonary Fibrosis

American journal of respiratory and critical care medicine, 2017-09, Vol.196 (6), p.756-761

2017

Volltextzugriff (PDF)

Second‐line and subsequent therapy and outcomes for follicular lymphoma in the United States: data from the observational National LymphoCare Study

British journal of haematology, 2019-02, Vol.184 (4), p.660-663

2019

Volltextzugriff (PDF)

Expanded access study of patients with advanced basal cell carcinoma treated with the Hedgehog pathway inhibitor, vismodegib

Journal of the American Academy of Dermatology, 2014-01, Vol.70 (1), p.60-69

2014

Volltextzugriff (PDF)

Disease-modifying effects of ranibizumab for central retinal vein occlusion

Graefe's archive for clinical and experimental ophthalmology, 2022-03, Vol.260 (3), p.799-805

2022

Volltextzugriff (PDF)

Disease, treatment, and outcome differences between men and women with follicular lymphoma in the United States

American journal of hematology, 2016-08, Vol.91 (8), p.770-775

2016

Volltextzugriff (PDF)

Assessing Real-World Racial Differences Among Patients With Metastatic Triple-Negative Breast Cancer in US Community Practices

Frontiers in public health, 2022-05, Vol.10, p.859113-859113

2022

Volltextzugriff (PDF)

Updated Integrated Analysis of the Efficacy and Safety of Entrectinib in Locally Advanced or Metastatic ROS1 Fusion-Positive Non-Small-Cell Lung Cancer

Journal of clinical oncology, 2021-04, Vol.39 (11), p.1253-1263

2021

Volltextzugriff (PDF)

Safety and efficacy of vismodegib in patients with basal cell carcinoma nevus syndrome: pooled analysis of two trials

Orphanet journal of rare diseases, 2016-09, Vol.11 (1), p.120-120, Article 120

2016

Volltextzugriff (PDF)

Timing of Peak Vision Gains in Patients with Neovascular Age-Related Macular Degeneration Treated with Ranibizumab

Ophthalmology retina, 2020-08, Vol.4 (8), p.760-766

2020

Volltextzugriff (PDF)

Safety and efficacy of vismodegib in patients aged ≥65 years with advanced basal cell carcinoma

Oncotarget, 2016-11, Vol.7 (46), p.76118-76124

2016

Volltextzugriff (PDF)

A single-arm, open-label, expanded access study of vemurafenib in patients with metastatic melanoma in the United States

The cancer journal (Sudbury, Mass.), 2014-01, Vol.20 (1), p.18-24

2014

Volltextzugriff (PDF)

Pirfenidone Reduces Respiratory-related Hospitalizations in Idiopathic Pulmonary Fibrosis

American journal of respiratory and critical care medicine, 2017-09, Vol.196 (6), p.756-761

2017

Volltextzugriff (PDF)

Abstract PS7-53: Assessing racial differences in patients with metastatic triple-negative breast cancer: Real-world evidence from US community oncology practices

Cancer research (Chicago, Ill.), 2021-02, Vol.81 (4_Supplement), p.PS7-53-PS7-53

2021

Volltextzugriff (PDF)

HOME CARDIAC SURVEILLANCE WITH ARTIFICIAL INTELLIGENCE DIGITAL PATIENT MONITORING DURING TREATMENT WITH PERTUZUMAB, TRASTUZUMAB AND HYALURONIDASE-ZZXF FOR HER2-POSITIVE BREAST CANCER (HARRIET): STUDY DESIGN AND RATIONALE

Journal of the American College of Cardiology, 2022-03, Vol.79 (9), p.2004

2022

Volltextzugriff (PDF)

evERA Breast Cancer (BC): Phase III study of giredestrant + everolimus vs exemestane + everolimus in patients (pts) with estrogen receptor-positive, HER2-negative locally advanced or metastatic BC (ER+, HER2– LA/mBC)

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.TPS1119-TPS1119

2023

Volltextzugriff (PDF)

Abstract P3-10-11: Entrectinib in NTRK fusion-positive breast cancer: Integrated analysis of patients enrolled in STARTRK-2, STARTRK-1 and ALKA-372-001

Cancer research (Chicago, Ill.), 2020-02, Vol.80 (4_Supplement), p.P3-P3-10-11

2020

Volltextzugriff (PDF)

Preliminary analysis of an expanded access study of the fixed-dose combination of pertuzumab (P) and trastuzumab (H) for subcutaneous injection (PH FDC SC) for at-home administration (admin) in patients (pts) with HER2-positive (HER2+) breast cancer (BC) during the COVID-19 pandemic

Journal of clinical oncology, 2022-06, Vol.40 (16_suppl), p.1515-1515

2022

Volltextzugriff (PDF)

Pirfenidone Reduces Respiratory-related Hospitalizations in Idiopathic Pulmonary Fibrosis

American journal of respiratory and critical care medicine, 2017-09, Vol.196 (6), p.756

2017

Volltextzugriff (PDF)

Abstract OT2-01-07: evERA Breast Cancer: A phase III study of giredestrant (GDC-9545) + everolimus vs exemestane + everolimus in patients with estrogen receptor+, HER2– locally advanced or metastatic breast cancer

Cancer research (Chicago, Ill.), 2023-03, Vol.83 (5_Supplement), p.OT2-01-07-OT2-01-07

2023

Volltextzugriff (PDF)

If the ratio of hazards r(t)=λe(t)/λc(t) does not depend on time t then the proportional hazards assumption holds

Journal of thoracic oncology, 2013-12, Vol.8 (12), p.e116-e116

2013

Volltextzugriff (PDF)

To the Editor

Journal of thoracic oncology, 2013-12, Vol.8 (12), p.e116-e116

2013

Volltextzugriff (PDF)

To the Editor

Journal of thoracic oncology, 2013-12, Vol.8 (12), p.e116

2013

Volltextzugriff (PDF)

BRAF V600 mutations in solid tumors, other than metastatic melanoma and papillary thyroid cancer, or multiple myeloma: a screening study

OncoTargets and therapy, 2017-02, Vol.10, p.965-971

2017

Volltextzugriff (PDF)

Overall response rate (ORR) in STEAM, a randomized, open-label, phase 2 trial of sequential and concurrent FOLFOXIRI-bevacizumab (BEV) vs FOLFOX-BEV for the first-line (1L) treatment (tx) of patients (pts) with metastatic colorectal cancer (mCRC)

Journal of clinical oncology, 2016-02, Vol.34 (4_suppl), p.492-492

2016

Volltextzugriff (PDF)

mutations in solid tumors, other than metastatic melanoma and papillary thyroid cancer, or multiple myeloma: a screening study

OncoTargets and therapy, 2017-01, Vol.10, p.965

2017

Volltextzugriff (PDF)

1 – 25 von 28

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(26)
Mit Volltextzugriff
(26)

Publikationsform

Artikel
(27)
Dissertationen
(1)

Sprache

Englisch
(28)

Erscheinungsjahr

n.n

Thema

Humans
(10)
Life Sciences & Biomedicine
(10)
Science & Technology
(10)
Female
(8)
Male
(8)
Middle Aged
(8)
Aged
(7)
Aged, 80 And Over
(6)
Adult
(5)
Treatment Outcome
(5)
Antineoplastic Agents - Therapeutic Use
(4)
Skin Neoplasms - Drug Therapy
(4)
Young Adult
(4)
Anilides - Adverse Effects
(3)
Anilides - Therapeutic Use
(3)
Antineoplastic Agents - Adverse Effects
(3)
Basal Cell Carcinoma
(3)
Carcinoma, Basal Cell - Drug Therapy
(3)
Mortality
(3)
Oncology
(3)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Pirfenidone Reduces Respiratory-related Hospitalizations in Idiopathic Pulmonary Fibrosis

Second‐line and subsequent therapy and outcomes for follicular lymphoma in the United States: data from the observational National LymphoCare Study

Expanded access study of patients with advanced basal cell carcinoma treated with the Hedgehog pathway inhibitor, vismodegib

Disease-modifying effects of ranibizumab for central retinal vein occlusion

Disease, treatment, and outcome differences between men and women with follicular lymphoma in the United States

Assessing Real-World Racial Differences Among Patients With Metastatic Triple-Negative Breast Cancer in US Community Practices

Updated Integrated Analysis of the Efficacy and Safety of Entrectinib in Locally Advanced or Metastatic ROS1 Fusion-Positive Non-Small-Cell Lung Cancer

Safety and efficacy of vismodegib in patients with basal cell carcinoma nevus syndrome: pooled analysis of two trials

Timing of Peak Vision Gains in Patients with Neovascular Age-Related Macular Degeneration Treated with Ranibizumab

Safety and efficacy of vismodegib in patients aged ≥65 years with advanced basal cell carcinoma

A single-arm, open-label, expanded access study of vemurafenib in patients with metastatic melanoma in the United States

Pirfenidone Reduces Respiratory-related Hospitalizations in Idiopathic Pulmonary Fibrosis

Abstract PS7-53: Assessing racial differences in patients with metastatic triple-negative breast cancer: Real-world evidence from US community oncology practices

HOME CARDIAC SURVEILLANCE WITH ARTIFICIAL INTELLIGENCE DIGITAL PATIENT MONITORING DURING TREATMENT WITH PERTUZUMAB, TRASTUZUMAB AND HYALURONIDASE-ZZXF FOR HER2-POSITIVE BREAST CANCER (HARRIET): STUDY DESIGN AND RATIONALE

evERA Breast Cancer (BC): Phase III study of giredestrant + everolimus vs exemestane + everolimus in patients (pts) with estrogen receptor-positive, HER2-negative locally advanced or metastatic BC (ER+, HER2– LA/mBC)

Abstract P3-10-11: Entrectinib in NTRK fusion-positive breast cancer: Integrated analysis of patients enrolled in STARTRK-2, STARTRK-1 and ALKA-372-001

Preliminary analysis of an expanded access study of the fixed-dose combination of pertuzumab (P) and trastuzumab (H) for subcutaneous injection (PH FDC SC) for at-home administration (admin) in patients (pts) with HER2-positive (HER2+) breast cancer (BC) during the COVID-19 pandemic

Pirfenidone Reduces Respiratory-related Hospitalizations in Idiopathic Pulmonary Fibrosis

Abstract OT2-01-07: evERA Breast Cancer: A phase III study of giredestrant (GDC-9545) + everolimus vs exemestane + everolimus in patients with estrogen receptor+, HER2– locally advanced or metastatic breast cancer

If the ratio of hazards r(t)=λe(t)/λc(t) does not depend on time t then the proportional hazards assumption holds

To the Editor

To the Editor

BRAF V600 mutations in solid tumors, other than metastatic melanoma and papillary thyroid cancer, or multiple myeloma: a screening study

Overall response rate (ORR) in STEAM, a randomized, open-label, phase 2 trial of sequential and concurrent FOLFOXIRI-bevacizumab (BEV) vs FOLFOX-BEV for the first-line (1L) treatment (tx) of patients (pts) with metastatic colorectal cancer (mCRC)

mutations in solid tumors, other than metastatic melanoma and papillary thyroid cancer, or multiple myeloma: a screening study

Suchergebnisse filtern